Wednesday, July 11, 2018 1:12:05 PM
First, the latest information on all trials can be found by reviewing the latest conference call (HERE) & the latest 10Q (HERE).
*All NCT numbers below are links to the trial page at clinicaltrials.gov
TPIV 200 for ovarian (NCT02978222): "Continuing to enroll patients as efficiently as possible and we remain on track to conduct a blinded interim analysis in 2019." This is the trial that is supposed to have interim results Q1 or Q2 next year so we are still on track.
TPIV 200 for TNBC (NCT02593227): "The data that we have is when we released the TPIV200 findings back in March." The whitepaper can be found HERE & the publication to AACR Clinical Cancer Research can be found HERE.
Combination trial of TPIV 200 & Durvalumab for ovarian (NCT02764333): "Enrollment in this single arm study was suspended as required by the final two stage design, while the first 27 patients were currently enrolled completed their treatment, and the planned interim analysis is conducted. Based on discussion with the study’s clinical investigators the data are still being analyzed and we anticipate reporting results as soon as they are released by the MSKCC." This should be the next data we see. I'm hoping sometime before year's end. If positive this could provide a good boost and keep SP propped up into early next year when data from the Tapimmune sponsored trial of TPIV 200 in ovarian is released.
TPIV 200 for TNBC funded by DOD w/ Mayo Clinic (NCT03012100): "Since we are not sponsors of this trial, you will need to reach out to the Mayo Clinic [with any questions]." I have done so and will post any response I receive.
TPIV 100/110: Mayo has already secured a grant funding from DoD to launch Phase 1B/2A clinical study in women with ductal carcinoma in situ or DCIS breast cancer. The DoD grant may also enable us to expand the types of cancers targeted by our HER2neu vaccine. While the timing of this study is driven by Mayo Clinic we look forward to providing an update as soon as patient enrollment begins. From the Q4 conference call, "the Department of Defense expressed interest in fully funding yet another Phase 2 clinical study to evaluate our five peptide HER2 vaccine, TPIV110, in combination with Herceptin in HER2 new positive breast cancer patients." I would hope to hear something about this new fully funded trial before year's end as well but no timeline has been given thus far.
Info on the Marker therapies HERE & HERE.
I have a couple of outstanding emails and as soon as, and if, I get responses I will post them here.
Friends don't let friends place market orders
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM